Hemostats Market

According to Stratistics MRC, the Global Hemostats Market is accounted for $2.7 billion in 2023 and is expected to reach $4.8 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Hemostats are medical instruments used to control bleeding by either clamping, sealing, or compressing blood vessels, tissues, or vessels. They are valuable tools in surgical procedures to ensure a bloodless surgical field, aiding in accurate and safe interventions. Hemostats help prevent excessive blood loss, minimizing the risk of hemorrhage and complications during surgery.

According to a report published by American Heart Association in July 2020, the annual number of Coronary Artery Bypass Graft (CABG) surgeries is around 240,000 in the U.S. All these trends are expected to increase demand for hemostatic agents.

Market Dynamics: 

Driver: 

Rising number of surgical procedures

As the global population grows and ages, the demand for surgical interventions continues to increase, spanning various medical fields, from cardiovascular and orthopedic surgeries to trauma and cancer-related procedures. Hemostatic agents play a crucial role in controlling bleeding during these surgeries, contributing to patient safety and surgical success. With advancements in surgical techniques and a broader array of surgical options available, the need for effective and efficient hemostatic tools becomes more pronounced. This growing surgical volume underscores the pivotal role hemostats play in maintaining hemostasis, reducing blood loss, and improving patient outcomes.

Restraint:

Limited use in emergency settings

While hemostatic agents are crucial in controlling bleeding during surgical procedures, their applicability in rapid and high-stress emergency situations, such as trauma care and battlefield medicine, can be restricted. In these scenarios, there is a need for hemostatic products that offer near-instantaneous and reliable hemostasis. Hemostats that require complex application procedures or specific conditions may not meet the demands of these critical situations. Overcoming this restraint requires the development of specialized hemostatic solutions designed for quick and effective use in emergencies, where every moment counts in saving lives and preventing severe hemorrhage.

Opportunity:

Healthcare cost reduction

By minimizing blood loss, reducing the need for blood transfusions, and shortening surgical times, hemostatic agents contribute to lower healthcare expenses. These cost-effective solutions improve resource allocation, reduce postoperative complications, and enhance patient outcomes, which can ultimately translate to reduced hospitalization costs and healthcare expenditures. In an environment where healthcare cost containment is a paramount concern, hemostatic products that offer both clinical effectiveness and economic advantages are well-positioned to address this opportunity and gain traction in the market.

Threat:

Stringent regulatory changes

Evolving regulations and heightened safety standards can impact the approval, formulation, and commercialization of hemostatic products. Compliance with these ever-changing regulations can be time-consuming and costly, leading to potential delays in market entry and increased development expenses. The challenge lies in adapting to new requirements while maintaining product safety and efficacy. Regulatory uncertainties and the need for comprehensive documentation add complexity to the development process. These factors can hinder innovation, limit the introduction of novel hemostatic solutions, and potentially reduce the market's ability to address the evolving needs of healthcare providers and patients.

Covid-19 Impact: 

The COVID-19 pandemic had a mixed impact on the hemostats market. While the demand for hemostatic agents remained high during critical surgeries and trauma care, the pandemic disrupted supply chains, affecting the availability of some products. Additionally, elective surgical procedures were postponed or canceled, temporarily reducing the overall market demand. As healthcare facilities focused on COVID-19 treatment, the attention to other medical needs, including hemostasis, fluctuated. However, the importance of maintaining a robust healthcare infrastructure and the need for hemostats in emergencies became more evident, potentially driving greater resilience in the market post-pandemic as healthcare systems adapt to meet future challenges.

The thrombin-based hemostats segment is expected to be the largest during the forecast period

The thrombin-based hemostats segment is expected to have a lucrative growth. These products contain thrombin, an enzyme responsible for initiating the blood clotting process. When applied to a bleeding site, thrombin-based hemostats accelerate clot formation by converting soluble fibrinogen into insoluble strands of fibrin, ultimately leading to the formation of a stable blood clot. Their versatility makes them suitable for a wide range of surgical procedures, from cardiovascular and orthopedic surgeries to liver resections and trauma care. Thrombin-based hemostats offer rapid and precise control over bleeding, reducing the risk of hemorrhage and associated complications. Their proven track record in achieving hemostasis continues to make them a trusted choice in the medical field, contributing to their prominence within the broader hemostats market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. These medical facilities, ranging from large academic medical centers to community hospitals, rely on hemostats to control bleeding during a diverse array of surgical procedures. Hemostatic agents are essential tools that ensure a bloodless surgical field, enabling healthcare providers to perform surgeries with precision and safety. The constant demand for surgical interventions, whether elective or emergency, underscores the importance of hemostats in hospitals. Moreover, the adoption of advanced surgical techniques, including minimally invasive procedures, further amplifies the need for effective hemostatic products, hospitals' ongoing focus on patient safety, successful surgical outcomes, and operational efficiency continues to drive the growth and development of the hemostats market.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market share. The region boasts a well-established healthcare infrastructure, advanced medical technology, and a high volume of surgical procedures. The demand for hemostatic agents and devices remains consistently strong across various medical specialties, from cardiac and orthopedic surgeries to trauma care. Stringent regulatory standards and a focus on patient safety drive the development and adoption of innovative hemostatic solutions. Additionally, the prevalence of chronic diseases and an aging population further amplifies the need for effective hemostats.

Region with highest CAGR:

The Asia Pacific region plays a significant role in the market and is projected to have the highest CAGR over the forecast period. The increasing healthcare investments, expanding healthcare infrastructure, and a growing patient population create a favorable environment for the adoption of hemostatic agents and devices. With rising surgical volumes, particularly in countries like China and India, the demand for effective hemostatic solutions is on the ascent. Additionally, the region's focus on affordable healthcare solutions, growing trend of medical tourism and access to medical care drives the market's growth. 

Key players in the market

Some of the key players in Hemostats market include Ethicon, Inc, Becton Dickinson and Company, Marine Polymer Technologies, Inc, Pfizer, Inc, Johnson & Johnson Services, Inc, Integra Lifesciences Corporation, Hemostatis LLC, Z-Medica LLC, Medtronic plc, Gelita Medical GmbH, Stryker Corporation, Baxter International, Inc, Teleflex Incorporated, Anika Therapeutics, Inc, B. Braun Melsungen AG and CR Bard, Inc.

Key Developments:

In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.

In July 2023, Baxter International (US) launched its PERCLOT Absorbable Hemostatic Powder in the US. This will allow the company to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for patients. 

Product Types Covered:
• Thrombin-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Other Product Types
 
Formulations Covered:
• Matrix & Gel Hemostats
• Sheet & Pad Hemostats
• Sponge Hemostats
• Powder Hemostats
• Other Formulations

Indications Covered:
• Closure
• Surgery
 
Applications Covered:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Plastic Surgery
• Other Applications

End Users Covered:
• Ambulatory Centers
• Hospitals
• Clinics
• Community Healthcare
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances